Purpose. To understand the diversity of porin disruption in Klebsiella pneumoniae, the major outer membrane protein (OMP) porins, OmpK35 and OmpK36, were examined in a set of isolates that did not harbour traditional carbapenem-hydrolysing enzymes, but nevertheless tested non-susceptible to ertapenem.
INTRODUCTION
Gram-negative pathogens with highly expressed BushJacoby group 1 or Ambler class C b-lactamase enzymes, known broadly as AmpCs, can prove resistant to carbapenems when combined with porin mutations that retard drug entry into the cell [1] [2] [3] [4] . Similarly, isolates harbouring extended-spectrum b-lactamases (ESBLs), which on their own do not normally confer carbapenem resistance, can be non-susceptible to carbapenems [5] , including ertapenem [3] when membrane permeability is reduced. In Klebsiella pneumoniae, the major outer membrane protein (OMP) porins, OmpK35 and OmpK36, homologs of the well-studied OmpF and OmpC, respectively, in Escherichia coli, have been implicated in reduced carbapenem susceptibility. For example, Doumith [6] illustrated that high-level ertapenem resistance (MIC!4 mg l À1 ) in K. pneumoniae was attributable to a combination of ESBLs with impermeability caused by loss of both OmpK35 and OmpK36, and in one case appeared to be due solely to porin defects. Similarly, Landman [7] demonstrated with some K. pneumoniae strains that carbapenem MICs increased with decreasing expression of OmpK36. In fact, spontaneous resistance mutants with reduced permeability have been reported to be selected for during carbapenem therapy [8] . Although this phenomenon is thought to be of limited importance epidemiologically as these mutants are often unstable and can revert back to susceptibility [9] , there are reports of outbreaks in southern Europe caused by ESBL-producing K. pneumoniae with porin mutations resistant to ertapenem [10] [11] [12] . Despite the fact that these types of porin mutations are thought to be reasonably common occurrences in K. pneumoniae, comprehensive global surveys of porin defects in combination with b-lactamase enzyme carriage in this species is lacking.
The Study for Monitoring Antimicrobial Resistance Trends (SMART) is an ongoing global surveillance project focused on determining in vitro resistance of clinical Gram-negative rods to a variety of antimicrobial agents from intra-abdominal infections since 2002, urinary tract infections since 2009 [13] and lower respiratory tract infections (since 2015) [14] . As a part of this effort, starting in 2008, subsets of isolates have been characterised molecularly for the presence of acquired b-lactamase genes. This study reports on the molecular characterisation and potential permeability alterations among a group of world-wide K. pneumoniae isolates collected from 2008 to 2014, non-susceptible to ertapenem but without detectable genes for enzymes known to hydrolyse carbapenems (i.e. bla NDM , bla KPC , bla VIM , bla IMP , and bla OXA-48 group).
METHODS

Bacterial strains and phenotypic antimicrobial susceptibility testing
Isolates were submitted as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART), which is a global surveillance examination of the antimicrobial drug susceptibility of clinical Gram-negative organisms. Isolates were sent to a central laboratory (International Health Management Associates, Schaumburg, IL) for confirmation of identification, susceptibility testing, and molecular characterization of b-lactamase genes. Identification of K. pneumoniae isolates was confirmed by MALDI-TOF (Bruker) or traditional biochemical analysis (RapID System, Remel). MICs and detection of phenotypic ESBL activity were determined using custom dehydrated Microscan broth microdilution panels (Siemens Medical Solutions Diagnostics) following manufacturer's recommendations for use, and Clinical and Laboratory Standards Institute (CLSI) guidelines and interpretive criteria [15] .
b-lactamase gene carriage screening Genomic DNA was extracted from overnight colonies grown on blood agar (Remel) using the QIAamp DNA Mini Kit and the QIAcube instrument (Qiagen) according to the manufacturer's instructions. To detect genes that encode b-lactamases (bla), five multiplex PCR reactions were employed as follows: (1) bla TEM , bla SHV , bla VEB , bla PER , bla-GES and bla SPM ; (2) bla IMP , bla VIM , bla OXA-48 , bla NDM and bla KPC ; (3) bla ACC , bla ACT, bla MIR , bla CMY , bla MOX , bla DHA and bla FOX ; (4) bla CTX-M-group-1 , bla CTX-M-group-2 and bla CTX-M-group-9 ; (5) bla CTX-M-group-8 and bla CTX-M-group-25 . All reactions were performed using the Multiplex PCR kit (Qiagen), except for the bla CTX-M-group-8 /bla CTX-M-group-25 duplex which utilised the Fast Cycling PCR kit (Qiagen), following the manufacturer's instructions, and using primer sets previous published [16] [17] [18] [19] [20] [21] [22] [23] . All detected b-lactamases, except for chromosomally-located AmpC enzymes endogenous to particular species, were amplified for sequencing with extragenic primers using the Fast Cycling PCR kit (Qiagen). ), were interrogated by porin gene sequencing. Genomic fragments containing the coding, upstream, and downstream regions from the ompK35 and ompK36 genes of several K. pneumoniae isolates available in the public databases were aligned using CLUSTAL software. Conserved primer sets were designed to amplify the full coding region (Table S1 , available in the online version of this article). PCR products were sent to an outside provider (GeneWiz, Inc.) for sequencing, and analysis was performed with SeqScape software (v. 2.7). Porin gene sequences were compared to those from K. pneumoniae ATCC 13883 and categorised as disrupted if analysis revealed an insertion and/or deletion causing a reading frameshift with a premature stop codon, nonsense point mutation, gross disruption by an insertion sequence, or repeated failure to amplify. Insertions and/or deletions that did not alter the reading frame were not considered disruptions, with two exceptions: (1) a six base pair insertion resulting in a glycine-aspartic acid 'GD' at amino acid positions 134-135 in the highly conserved OmpK36 L3 loop that is associated with high doripenem MICs [24] , and (2) a six base pair insertion leading to an aspartic acid-threonine 'DT' at amino acid positions 137-138, also in the L3 loop, that has been shown to be associated with increased ertapenem MICs [10] .
OMP protein purification
Outer membrane purification was performed following a modification of methods utilised by Carlone, et al. [25] and Woodford [26] . In brief, K. pneumoniae were grown in both high osmolarity media (LB broth, BD) and low osmolarity media (Nutrient broth, BD). The expression of OmpK35 and OmpK36 is at least partially regulated by osmolarity, homologous to the osmoregulatory process involving the OmpC and OmpF porins, respectively, in Escherichia coli [27] . Logarithmic phase cultures were harvested by centrifugation at 5000 g for 10 min at 4
C to pellet cells. Pellets were washed with cold 10 mM HEPES (pH 7.4) and centrifuged as before. Pellets were again re-suspended in cold 10 mM HEPES and sonicated on ice utilising three bursts for 30 s each at 40 W and amplitude setting at 50 %, with an intervening 30 s cooling period. Unbroken cells and debris were pelleted at 3000 g for 10 min at 4 C and the supernatant transferred to a new tube and centrifuged at max speed (14 000 g) for 30 min at 4 C. The protein pellet was resuspended in 0.2 ml of 10 mM HEPES, and cytoplasmic membrane proteins were then solubilised by incubation in an equal volume of 2 % sarcosine/10 mM HEPES (pH 7.4) buffer for 30 min at room temperature. Outer membrane proteins were retrieved by centrifugation at max speed (14 000 g) for 30 min at 4 C and resuspended in 100 µl of molecular biology grade water. Protein concentration was determined by colorimetric Bradford assays using Pierce Coomassie Blue Protein Reagent (ThermoFisher). Electrophoretic SDS-PAGE analysis of the OMPs was performed using 12 % acrylamide Mini-PROTEAN TGX precast gels (Bio-Rad), following the sample preparation recommended by the manufacturer. Five µg protein was used for each sample. During each experimental batch, the ertapenem-susceptible strain K. pneumoniae ATCC 13883 was grown in both the high and low-salt media, and OMPs purified as a control. Under high osmolarity conditions, this strain expresses predominantly OmpK36, whereas under low osmolarity conditions it expresses both the OmpK35 and OmpK36 porins [28, 29] . ). Screening for b-lactamases was carried out on 1702 samples, either using a commercial microarray system (Check-MDR CT101, Check-Points B. V.) or a more complete multiplex PCR screen [Note: isolates from China were not available for molecular analysis, and only years 2008-2009 from India were available]. The majority of those examined, 1142 (67.1 %), harboured a known carbapenemase(s) gene (bla NDM , bla KPC , bla VIM , bla IMP , and bla OXA-48 group). Of the remainder, 487 isolates from 47 countries ( Table 1) and diverse infections sources, including the urinary tract (n=220), gastrointestinal tract (n=110), peritoneal fluid (n=90) and abscess/pus (n=59) were investigated for permeability defects. Eight included isolates were submitted to the SMART program without infection source specified. The b-lactamase genes detected in this collection of isolates are shown in Table 2 . The vast majority (473/487, 97.1 %) contained an extended-spectrum b-lactamase and/or AmpC-type b-lactamase gene, with the widespread ESBL CTX-M-15 variant the most abundantly represented. Twelve isolates harbored just penicillinases, and for one isolate, none of the b-lactamases that were part of the standard screen was observed, although upon further characterisation this isolate was found to contain the chromosomal penicillinase, bla OKP .
Porin gene sequence analysis Analysis of the full-length porin gene sequences revealed that the majority of isolates, 404/487 (83.0 %) possessed at least one gross genetic lesion (insertion and/or deletion causing a premature stop codon, insertion sequence disruption, etc.) in either the OmpK35 or OmpK36 encoding gene. The frequency of types of mutations observed in the collection for each gene is provided in Table 3 . 
OMP analysis
After DNA sequence analysis, 83 K. pneumoniae isolates remained that did not exhibit a clear genetic disruption in either major porin gene. The OMPs of this set were analysed by SDS-PAGE, and the vast majority, 91.6 % (76/83), were shown to exhibit some variation of at least one of the major porins when compared to the ertapenem-sensitive control strain, K. pneumoniae ATCC 13883. Overall, 73.5 % (61/ 83), apparently were lacking in OmpK35 production, a phenomenon reported to be a common occurrence in ESBLharbouring K. pneumoniae [6, 7, 24, 30]. Another 30.1 % (25/83) exhibited loss, or severely reduced protein expression, of OmpK36 either alone or in combination with OmpK35 loss. Two (2.4 %) were considered uninterpretable, as the protein products could not be identified clearly based on their production in the high-and low-osmolarity media. Only five of the 83 isolates, (6.0 %), produced an OMP profile identical to the ertapenem-sensitive control strain. An example of outer membrane profiles, illustrating porin loss compared to K. pneumoniae ATCC 13883 is provided in Fig. 1 .
DISCUSSION
Disruption of normal porin expression in ESBL-producing K. pneumoniae has been shown previously to reduce susceptibility to carbapenems in strains collected worldwide [31] [32] [33] [34] , with ertapenem the most sensitive among the clinically useful carbapenems to permeability changes [6, 35] . Many studies have confirmed the role of OmpK36, but the contribution of OmpK35 permeability variation to carbapenem resistance has not been definitively established, with some studies suggesting OmpK35 is not involved [27, 28, 36, 37] . However, Domenech-Sanchez [38] demonstrated that complementation of a double ompK35-ompK36 mutant with OmpK35 alone decreased MICs of cephalosporins and meropenem >128-fold and decreased MIC of imipenem more than eightfold, suggesting that the OmpK35 porin does play some role in entry of these compounds into the cell. At the protein level, our examination of isolates without gross genetic disruptions in either porin confirms previous findings that the majority K. pneumoniae isolates carrying *Insertion of glycine-aspartic acid residues (GD) at amino acid positions 134-135 in the OmpK36 L3 loop is associated with elevated doripenem MICs [24] . †Not applicable. ‡Insertion of aspartic acid-threonine residues (DT) at amino acid positions 137-138 in the L3 loop of OmpK36 is associated with increased ertapenem MICs [10] .
ESBLs solely express OmpK36 with OmpK35 lacking [27] . Among the subset of organisms with MIC=1 mg l
À1
(n=160), a mutation in ompK35 was the most common genotype observed (80/160, 50 %), and in combination with the fact that the majority do not express OmpK35, suggests that OmpK35 loss may afford the cell low levels of resistance to ertapenem when an ESBL or AmpC is present. On the other hand, clear disruptions of both major porins at the nucleotide level was very common among the group of isolates with ertapenem MICs>4 mg l À1 (115/190, 60.5 %) suggesting both porins may need to be inactive to provide these high levels of resistance. However, at least at the genetic level, this association is not absolute, as several isolates in the collection with mutations in both major porins exhibited ertapenem MICs<4 mg l
. The L3 internal loop in OmpK36 is highly conserved and likely constitutes the porin channel eyelet [39, 40] , and changes to this region in homologous OMPs in Escherichia coli and Enterobacter aerogenes have been shown to alter pore properties [41] [42] [43] . Two particular mutations of the OmpK36 encoding gene observed in this study affect the L3 region, and both have been shown previously to be involved in decreased susceptibility to carbapenems. Nine isolates in this collection from Brazil (n=4), Estonia (n=3), Serbia (n=1) and South Africa (n=1) possessed the 'ompK36V' variant described by Garcia-Fernandez [10] that is marked by two additional amino acids, an aspartic acid and a threonine residue, at positions 137 and 138. This mutation in K. pneumoniae was shown to be associated with ertapenem resistance and reduced susceptibility to meropenem, but the susceptibility to imipenem was maintained. A second variant also possesses an insertion in the L3 loop region of the OmpK36 protein, with glycine and aspartic acid residues at amino acid positions 134 and 135, and this alteration was reported by Clancy, et al. [24] to be associated with resistance to doripenem. This insertion was relatively common in our collection appearing in the sequence of 100 isolates from Africa (n=13), Europe (n=18), Latin America (n=58), North America (n=1) and Asia (n=10.)
In summary, this large-scale global survey illustrates that a great diversity of major porin disruptions in K. pneumoniae can be associated with non-susceptibility to ertapenem. Of the set of 487 isolates examined here, there remained only five with wild-type OMP profiles via SDS-PAGE, in which gross lesions or expression level changes could not be identified in either major porin gene. For these, all except one did show some variation in DNA sequence when compared to the ompK35 and/or ompK36 sequence of the control K. pneumoniae ATCC 13883 (in-frame insertions/deletions, non-conservative amino acid substitutions, etc.); however, without further investigation it is unknown whether these differences are important for porin function. Only one isolate in the collection exhibited wild-type porin sequence at the DNA level and an OMP profile identical to K. pneumoniae ATCC 13883. This organism, with an ertapenem MIC=1 mg l À1 , did harbour a CTX-M-15 ESBL, but this alone should not account for the non-susceptibility. This strain could harbour an alternative carbapenemase enzyme not part of our standard screen, or possess a mechanism for resistance such as up-regulated efflux pumps [44] . As previously reported [35] , our data support the finding that among carbapenems, ertapenem appears especially sensitive to permeability defects, as the majority (420/487, 86.2 %) of the collection remained susceptible to imipenem (MIC 1 mg l
) by CLSI breakpoints [15] . Nevertheless, ertapenem remains an effective drug against K. pneumoniae, however vigilance regarding non-transmissible resistance factors such as porin mutations is warranted as they are widespread, and under the selective pressure could result in local clonal outbreaks.
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